GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ZELTIQ Aesthetics Inc (NAS:ZLTQ) » Definitions » Cash-to-Debt

ZELTIQ Aesthetics (ZELTIQ Aesthetics) Cash-to-Debt : No Debt (1) (As of Dec. 2016)


View and export this data going back to 2011. Start your Free Trial

What is ZELTIQ Aesthetics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. ZELTIQ Aesthetics's cash to debt ratio for the quarter that ended in Dec. 2016 was No Debt (1).

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, ZELTIQ Aesthetics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2016.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for ZELTIQ Aesthetics's Cash-to-Debt or its related term are showing as below:

ZLTQ's Cash-to-Debt is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.875
* Ranked among companies with meaningful Cash-to-Debt only.

ZELTIQ Aesthetics Cash-to-Debt Historical Data

The historical data trend for ZELTIQ Aesthetics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

ZELTIQ Aesthetics Cash-to-Debt Chart

ZELTIQ Aesthetics Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Cash-to-Debt
Get a 7-Day Free Trial No Debt No Debt 117.63 185.41 No Debt

ZELTIQ Aesthetics Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 185.41 165.24 255.86 No Debt No Debt

Competitive Comparison of ZELTIQ Aesthetics's Cash-to-Debt

For the Medical Devices subindustry, ZELTIQ Aesthetics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ZELTIQ Aesthetics's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ZELTIQ Aesthetics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where ZELTIQ Aesthetics's Cash-to-Debt falls into.



ZELTIQ Aesthetics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

ZELTIQ Aesthetics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2016 is calculated as:

ZELTIQ Aesthetics had no debt (1).

ZELTIQ Aesthetics's Cash to Debt Ratio for the quarter that ended in Dec. 2016 is calculated as:

ZELTIQ Aesthetics had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ZELTIQ Aesthetics  (NAS:ZLTQ) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


ZELTIQ Aesthetics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of ZELTIQ Aesthetics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


ZELTIQ Aesthetics (ZELTIQ Aesthetics) Business Description

Traded in Other Exchanges
N/A
Address
ZELTIQ Aesthetics Inc was incorporated in Delaware in March 2005 as Juniper Medical, Inc. In July 2007, it changed its name to ZELTIQ Aesthetics, Inc. ZELTIQ Aesthetics, Inc. is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled cooling technology platform. Its first commercial product, the CoolSculpting system, is designed to selectively reduce stubborn fat bulges. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues.
Executives
Todd Erik Zavodnick officer: President, International C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Bradley Hauser officer: SVP, Research and Development C/O ZELTIQ AESTHETICS, INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
Danika R Harrison officer: SVP of Global Marketing C/O ZELTIQ AESTHETICS, INC. 4410 ROSEWOOD DRIVE PLEASANTON CA 94588
Mark J Foley director, officer: President and CEO ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Taylor C. Harris officer: SVP & Chief Financial Officer 6035 STONERIDGE DRIVE, PLEASANTON CA 94588
Kevin C Oboyle director 5964 LA PLACE COURT, CARLSBAD CA 92008
Mary Fisher director C/O ACORDA THERAPEUTICS, INC., 15 SKYLINE DRIVE, HAWTHORNE NY 10532
D Keith Grossman director
Andrew N Schiff director, 10 percent owner PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Keith J Sullivan officer: CCO, President, North America C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
Patrick F. Williams officer: SVP & CFO C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
Leonard C Debenedictis officer: Chief Technical Officer C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
Bryan E Roberts director C/O VENROCK ASSOCIATES, 2494 SAND HILL ROAD STE 200, MENLO PARK CA 94025
Jean George director CRITICAL THERAPEUTICS INC, 60 WESTVIEW STREET, LEXINGTON MA 02421
Aisling Capital Iii Lp 10 percent owner 888 Seventh Avenue, 30th Fl, New York NY 10106

ZELTIQ Aesthetics (ZELTIQ Aesthetics) Headlines

No Headlines